• CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrate
• The unique degradation profile supports the strong competitive potential of the program
• Compelling pre-clinical data generated demonstrating HCC tumor regression
• CT-01 on track to enter clinical development in 2023

Wroclaw, Poland, April 11, 2022 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces the molecular targets of one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC).

Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with essential function in tumorigenesis. GSPT1 is a protein involved in the termination of translation, a process in which ribosomes synthesize proteins after the transcription of DNA to RNA. There is a demonstrated link between GSPT1 degradation and antitumor activity. SALL4 is a transcription factor expressed in the human fetal liver and silenced in adults but often re-expressed in HCC patients, which correlates with poor prognosis.

"The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics. "We have already reported compelling pre-clinical data showing that CT-01 candidate compounds induced strong tumor regression in a Hep 3B2.1-7 mouse model of human HCC. This compelling efficacy data, coupled with the unique degradation profile announced today, support our growing confidence in the strong scientific, medical and competitive value of the project."

Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023.

About Project CT-01 and HCC

The purpose of Project CT-01 is to develop, based on targeted protein degradation technology, a drug candidate which will stop the progress of hepatocellular carcinoma (HCC) and potentially offer significant benefits for patients. HCC, a form of liver cancer, constitutes a significant unmet medical need since most patients are diagnosed at a late stage of the disease, and present treatments bring limited benefits in terms of overall survival rate. With ~700,000 new cases each year, HCC constitutes the second most common cause of cancer mortality. In patients diagnosed early, surgical removal of the tumour remains the only effective therapy. In unresectable HCC, the best reported outcome is the combination of Atezolizumab (Tecentriq®) plus Bevacizumab (Avastin®), where 19.2 months median Overall Survival (OS) and 29.8% Overall Response Rate (ORR) were reported in the IMbrave150 study, indicating that there remains a dramatic need for new treatments.

About Captor Therapeutics

Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.  

More information on Captor Therapeutics is available at: http://www.captortherapeutics.com

LinkedIn: @CaptorTherapeutics

Twitter: @CaptorTherapeu1

 

For further information, please contact:

Polish Media and Investor relations: Point of View Jakub Radzewicz +48 601 155 582

International Investor Relations: LifeSci Advisors Guillaume van Renterghem +41 (0)76 735 01 31 gvanrenterghemmn64@lifesciadvisors.com